V-Bio Ventures
Venture capitalGhent · Seed–Growth · 13 people tracked
Investment thesis
V-Bio Ventures backs private life science companies with differentiated technologies that address unmet needs and offer high societal or environmental impact potential. The fund focuses on therapeutics, spanning both drug discovery and drug development, and co-creates startups in addition to investing in early- to mid-stage ventures. It maintains a preferred relationship with the Belgian research institute VIB, building some companies on VIB-derived innovation, while also sourcing deals from other research institutes, entrepreneurial initiatives, and corporate spin-outs. The firm concentrates geographically on Europe and offers more than capital through its network and sector expertise.
Source: firm website, verified Aug 7, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 12 of 21 portfolio companiesBiotech ×12Healthtech ×5Deep Tech ×4AgTech ×3Medical Devices ×3AI & Machine Learning ×1FoodTech ×1
HQs:Belgium×2France×1Italy×1United States×1
Investments · 21 tracked
founders shown can be your intro pathProtealis breeds legume crops such as soybeans and yellow peas and develops proprietary seed coatings with nitrogen-fixing bacteria adapted to the European climate.
AgTechBiotechFoodTechGent, BE
Benjamin Laga(Co-founder & CEO)Jonas Aper(Co-founder & Director of Breeding)
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)Pietro Faccioli(Co-founder)Giovanni Spagnolli(Co-founder, CTO)Maria Letizia Barreca(Co-founder)Graziano Lolli(Co-founder)
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors targeting fibro-inflammation, with a focus on treating fibrotic diseases including Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis.
BiotechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)
Animab is a biotechnology company developing oral antibody-based products that target intestinal pathogens to improve gut health in livestock, with a focus on protecting piglets during the post-weaning stage.
AgTechBiotechDeep Tech
Aphea.Bio develops biological crop protection products and biostimulants, including bioinsecticides targeting crop pests.
AgTechBiotech
Arc Therapeutics is a stealth-stage biopharmaceutical company developing medicines for central nervous system (CNS) conditions with high unmet medical needs.
BiotechHealthtech
Astrivax develops virus-targeted immunotherapies using its Launch-iT platform to eliminate cancer-causing viruses before they lead to disease, with an initial focus on HPV-driven cancers.
BiotechHealthtech
ATB Therapeutics develops targeted antibody therapies, including its "atbody" format, for hematological malignancies, autoimmune diseases, and solid tumors.
BiotechHealthtech
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
Biodol Therapeutics is a biotech company developing proprietary FLT3 inhibitors (BDT compounds) at the preclinical stage to treat neuropathic and chronic pain, including opioid-combination indications.
BiotechMedical DevicesMontpellier, FR
Orions Bio discovers, designs and engineers molecules that connect proteins on and within cells to reprogram disease-driving processes or activate immune responses.
BiotechDeep TechHealthtechNewton, US
Griet Vanpoucke, Ph.D.(Director)Steven R. Gullans, Ph.D.(Director)Nikolai Kley, Ph.D.(Executive Officer, Director)
Frequently asked questions
- What stage does V-Bio Ventures invest at?
- V-Bio Ventures invests at the Seed, Series A, Series B, Growth stages.
- What is V-Bio Ventures's typical check size?
- V-Bio Ventures typically writes checks of $270K – $2.2M.
- What sectors does V-Bio Ventures focus on?
- V-Bio Ventures focuses on AgTech, Biotech, Healthtech, Longevity, Medical Devices.
- Where is V-Bio Ventures located?
- V-Bio Ventures is headquartered in Ghent, BE.
Images
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.
AgeTech Capital is a purpose-driven private market investment firm backing technology solutions that support healthier, wealthier and more fulfilling aging.
Brookstreet Equity Partners LLP is a family-office-originated GP established by shipping and principal-capital families, operating as an institutional investment manager focused on AI-driven investments across digital transformation, energy transition, longevity, and defence technology.